
FIGURE 2 Management of Immune-Related Diarrhea/Colitis^{1,4,5,10,13,14,17-19}

Background: It is important to rule out other etiologies that may be responsible for diarrhea, such as *C.difficile* infections. Severe diarrhea has been observed in patients treated with immune therapy. The median time to onset is 6 to 8 weeks for ipilimumab and nivolumab, and 3.4 months for pembrolizumab. Diarrhea/colitis appears to be less frequent with PD-1 blockade than with CTLA-4 blockade.



 \pm loperamide 4 mg followed by 2 mg q4h or after every loose BM until diarrhea-free for 12hrs (max 16 mg/day)

† or equivalent

^oRefer to CCO Diarrhea Guidelines: https://www.cancercareontario.ca/en/symptom-management/3151

* If infliximab is contraindicated (possibility of perforation, sepsis, TB, NYHA 3/4 CHF), consider mycophenolate mofetil or other immunosuppressive agents